1
|
Fili M, Astrahan M, Stålhammar G. Long-term outcomes after enucleation or plaque brachytherapy of choroidal melanomas touching the optic disc. Brachytherapy 2021; 20:1245-1256. [PMID: 34253461 DOI: 10.1016/j.brachy.2021.05.162] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2021] [Revised: 05/13/2021] [Accepted: 05/27/2021] [Indexed: 11/17/2022]
Abstract
PURPOSE To investigate local and systemic outcomes after enucleation, brachytherapy with ruthenium-106, iodine-125, notched and non-notched plaques and transpupillary thermotherapy (TTT) of choroidal melanomas touching the optic disc. METHODS AND MATERIALS All patients treated for choroidal melanoma touching the optic disc at St. Erik Eye Hospital, Stockholm, Sweden between 1984 and 2015 (n = 165) were included. Retrospective clinicopathological data was collected and 3D dosimetry performed. RESULTS Ninety-five patients (58 %) had been treated with ruthenium-106 brachytherapy, 21 (13 %) with iodine-125 brachytherapy and 49 (30 %) with enucleation. Median follow-up was 12.3 years. In simulations, some tumor areas were underdosed with non-notched plaques. Fifty of 116 patients (43 %) underwent a secondary brachytherapy (n = 5), enucleation (n = 29) or TTT (n = 16). In multivariate Cox Regressions, there were no significant differences in the risk for tumor progression or lack of regression between radioisotopes and notched and non-notched plaques. Adding TTT did not reduce the risk for a second treatment. The number of clock hours of circumpapillary tumor growth did not correlate to the risk for treatment failure or mortality. There were no significant differences in melanoma-related mortality for any treatment including enucleation. Kaplan-Meier disease-specific survival was 77 % at 5 years, 72 % at 10 years and 67 % at 20 years. CONCLUSION Plaque brachytherapy of choroidal melanomas touching the optic disc entails a two to threefold increased risk for treatment failure. This risk is similar between radioisotopes, notched and non-notched plaque designs and if TTT is used or not. The high rate of treatment failure does not lead to increased mortality.
Collapse
Affiliation(s)
- Maria Fili
- Ophthalmic Pathology and Oncology Service, St. Erik Eye Hospital, Stockholm, Sweden; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | - Melvin Astrahan
- Department of Radiation Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA
| | - Gustav Stålhammar
- Ophthalmic Pathology and Oncology Service, St. Erik Eye Hospital, Stockholm, Sweden; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
| |
Collapse
|
2
|
Thomson RM, Furutani KM, Kaulich TW, Mourtada F, Rivard MJ, Soares CG, Vanneste FM, Melhus CS. AAPM recommendations on medical physics practices for ocular plaque brachytherapy: Report of task group 221. Med Phys 2020; 47:e92-e124. [PMID: 31883269 DOI: 10.1002/mp.13996] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2018] [Revised: 11/12/2019] [Accepted: 12/23/2019] [Indexed: 12/14/2022] Open
Abstract
The American Association of Physicists in Medicine (AAPM) formed Task Group 221 (TG-221) to discuss a generalized commissioning process, quality management considerations, and clinical physics practice standards for ocular plaque brachytherapy. The purpose of this report is also, in part, to aid the clinician to implement recommendations of the AAPM TG-129 report, which placed emphasis on dosimetric considerations for ocular brachytherapy applicators used in the Collaborative Ocular Melanoma Study (COMS). This report is intended to assist medical physicists in establishing a new ocular brachytherapy program and, for existing programs, in reviewing and updating clinical practices. The report scope includes photon- and beta-emitting sources and source:applicator combinations. Dosimetric studies for photon and beta sources are reviewed to summarize the salient issues and provide references for additional study. The components of an ocular plaque brachytherapy quality management program are discussed, including radiation safety considerations, source calibration methodology, applicator commissioning, imaging quality assurance tests for treatment planning, treatment planning strategies, and treatment planning system commissioning. Finally, specific guidelines for commissioning an ocular plaque brachytherapy program, clinical physics practice standards in ocular plaque brachytherapy, and other areas reflecting the need for specialized treatment planning systems, measurement phantoms, and detectors (among other topics) to support the clinical practice of ocular brachytherapy are presented. Expected future advances and developments for ocular brachytherapy are discussed.
Collapse
Affiliation(s)
- Rowan M Thomson
- Carleton Laboratory for Radiotherapy Physics, Physics Department, Carleton University, Ottawa, ON, K1S 5B6, Canada
| | - Keith M Furutani
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN, 55905, USA
| | - Theodor W Kaulich
- Department of Medical Physics, University of Tübingen, 72074, Tübingen, Germany
| | - Firas Mourtada
- Department of Radiation Oncology, Christiana Care Hospital, Newark, DE, 19713, USA
| | - Mark J Rivard
- Department of Radiation Oncology, Warren Alpert Medical School of Brown University, Providence, RI, 02903, USA
| | | | | | - Christopher S Melhus
- Department of Radiation Oncology, Tufts University School of Medicine, Boston, MA, 02111, USA
| |
Collapse
|
3
|
Filì M, Trocme E, Bergman L, See TRO, André H, Bartuma K, Girnita L, All-Eriksson C, Seregard S, Stålhammar G. Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm. Br J Ophthalmol 2019; 104:26-32. [DOI: 10.1136/bjophthalmol-2018-313419] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2018] [Revised: 02/08/2019] [Accepted: 03/05/2019] [Indexed: 02/03/2023]
Abstract
BackgroundEpiscleral brachytherapy is the most common eye-preserving treatment for medium-sized choroidal melanomas. γ-emitting iodine-125 (125I) and β-emitting ruthenium-106 (106Ru) are widely used. The latter is however generally reserved for thinner tumours (<6 mm). In this study, we compare ocular and patient survival in thicker tumours treated with the respective radioisotope.MethodsAll patients with ≥5.5 mm thick choroidal melanomas who were treated with plaque brachytherapy at a single institution between 1 November 1979 and 31 December 2015 were included (n=571). Size-controlled Cox regression HRs for postbrachytherapy enucleation, repeated brachytherapy and melanoma-related mortality were calculated, as well as Kaplan-Meier disease-specific survival and relative 10-year survival in matched subgroups.Results317 patients were treated with 106Ru and 254 with 125I. The rate of repeated brachytherapy was significantly higher among patients treated with 106Ru (8%) than with 125I (1%, p<0.001). Size-controlled Cox regression HRs for postbrachytherapy enucleation (125I vs 106Ru 0.7, p=0.083) and melanoma-related mortality were not significant (125I vs 106Ru 1.1, p=0.63). Similarly, Kaplan-Meier disease-specific and relative 10-year survival was comparable in matched groups of 5.5–7.4 mm (relative survival 106Ru 59%, 125I 56%) and ≥7.5 mm thick tumours (relative survival 106Ru 46%, 125I 44%).ConclusionsRates of repeated brachytherapy were significantly higher among patients treated with 106Ru versus 125I for thick choroidal melanomas. There were, however, no significant differences in rates of enucleation or patient survival.
Collapse
|
4
|
Kanavi MR, Asadi S, Balagholi S, Alikarami F, Nosrati H, Ahmadieh H. Gamma irradiation of ocular melanoma and lymphoma cells in the presence of gold nanoparticles: in vitro study. J Appl Clin Med Phys 2018; 19:268-275. [PMID: 29707895 PMCID: PMC5978644 DOI: 10.1002/acm2.12336] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2017] [Revised: 03/05/2018] [Accepted: 03/08/2018] [Indexed: 12/13/2022] Open
Abstract
The aim of this work was to determine whether conjugation of cultivated choroidal melanoma and Burkitt's lymphoma cells with gold nanoparticles (GNPs) is beneficial for these series of ocular cancer patients. GNPs are radiosensitizers and can sensitize tumors to radiotherapy.This application has been examined in several tumor types, but not in choroidal melanoma. This study shows the results of in vitro study on the choroidal melanoma and also Burkitt's lymphoma cells in the presence of GNPs during continuous gamma irradiation. Cytotoxicity of GNPs were assessed for five different concentrations then cultured melanoma and Burkitt's lymphoma cells were irradiated with a Gamma source in the presence and absence of NPs. Incubation of melanoma cells with GNP concentrations below 100 μg/ml, accompanied by gamma irradiation, increased cell death (P value = 0.016) . In the absence of irradiation, GNPs at these concentrations did not affect cultured melanoma cell metabolism. Reduced cell viability resulted from a significant increase in absorbed energy by the tumor. Moreover, GNP concentrations higher than 200 μg/ml induced cytotoxicity in melanoma cells. Cytotoxicity assay in GNPs-loaded Burkitt's lymphoma cells showed a slight decrease in cell viability at 50 μg/ml and clear cytotoxicity at concentrations higher than 100 μg/ml (P value = 0.035). Concentration and proper injection doses of GNPs in sensitive tissues such as the human eye are important variables yet to be determined.This is the first report of choroidal melanoma dosimetry performed in the presence of GNPs and provides valuable insights into future therapeutic approaches. Further in vitro study with more different sizes and concentrations is needed to determine the optimum size and concentration before any clinical research in this regard.
Collapse
Affiliation(s)
- Mozhgan Rezaei Kanavi
- Ocular Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Somayeh Asadi
- Ocular Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.,Ophtalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Sahar Balagholi
- Ocular Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.,Department of Hematology, Faculty of Allied Medicine, Tehran University of Medical Science, Tehran, Iran
| | - Fatemeh Alikarami
- Department of Hematology, Faculty of Allied Medicine, Iran University of Medical Science, Tehran, Iran
| | - Hassan Nosrati
- Radiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
| | - Hamid Ahmadieh
- Ophtalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| |
Collapse
|
5
|
The retina dose-area histogram: a metric for quantitatively comparing rival eye plaque treatment options. J Contemp Brachytherapy 2013; 5:23-32. [PMID: 23634152 PMCID: PMC3635050 DOI: 10.5114/jcb.2013.34450] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2013] [Revised: 03/11/2013] [Accepted: 03/20/2013] [Indexed: 12/25/2022] Open
Abstract
PURPOSE Episcleral plaques have a history of over a half century in the delivery of radiation therapy to intraocular tumors such as choroidal melanoma. Although the tumor control rate is high, vision-impairing complications subsequent to treatment remain an issue. Notable, late complications are radiation retinopathy and maculopathy. The obvious way to reduce the risk of radiation damage to the retina is to conform the prescribed isodose surface to the tumor base and to reduce the dose delivered to the surrounding healthy retina, especially the macula. Using a fusion of fundus photography, ultrasound and CT images, tumor size, shape and location within the eye can be accurately simulated as part of the radiation planning process. In this work an adaptation of the dose-volume histogram (DVH), the retina dose-area histogram (RDAH) is introduced as a metric to help compare rival plaque designs and conformal treatment planning options with the goal of reducing radiation retinopathy. MATERIAL AND METHODS The RDAH is calculated by transforming a digitized fundus-photo collage of the tumor into a rasterized polar map of the retinal surface known as a retinal diagram (RD). The perimeter of the tumor base is digitized on the RD and its area computed. Area and radiation dose are calculated for every pixel in the RD. RESULTS The areal resolution of the RDAH is a function of the pixel resolution of the raster image used to display the RD and the number of polygon edges used to digitize the perimeter of the tumor base. A practical demonstration is presented. CONCLUSIONS The RDAH provides a quantitative metric by which episcleral plaque treatment plan options may be evaluated and compared in order to confirm adequate dosimetric coverage of the tumor and margin, and to help minimize dose to the macula and retina.
Collapse
|
6
|
Chiu-Tsao ST, Astrahan MA, Finger PT, Followill DS, Meigooni AS, Melhus CS, Mourtada F, Napolitano ME, Nath R, Rivard MJ, Rogers DWO, Thomson RM. Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS. Med Phys 2012; 39:6161-84. [PMID: 23039655 DOI: 10.1118/1.4749933] [Citation(s) in RCA: 146] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Dosimetry of eye plaques for ocular tumors presents unique challenges in brachytherapy. The challenges in accurate dosimetry are in part related to the steep dose gradient in the tumor and critical structures that are within millimeters of radioactive sources. In most clinical applications, calculations of dose distributions around eye plaques assume a homogenous water medium and full scatter conditions. Recent Monte Carlo (MC)-based eye-plaque dosimetry simulations have demonstrated that the perturbation effects of heterogeneous materials in eye plaques, including the gold-alloy backing and Silastic insert, can be calculated with reasonable accuracy. Even additional levels of complexity introduced through the use of gold foil "seed-guides" and custom-designed plaques can be calculated accurately using modern MC techniques. Simulations accounting for the aforementioned complexities indicate dose discrepancies exceeding a factor of ten to selected critical structures compared to conventional dose calculations. Task Group 129 was formed to review the literature; re-examine the current dosimetry calculation formalism; and make recommendations for eye-plaque dosimetry, including evaluation of brachytherapy source dosimetry parameters and heterogeneity correction factors. A literature review identified modern assessments of dose calculations for Collaborative Ocular Melanoma Study (COMS) design plaques, including MC analyses and an intercomparison of treatment planning systems (TPS) detailing differences between homogeneous and heterogeneous plaque calculations using the American Association of Physicists in Medicine (AAPM) TG-43U1 brachytherapy dosimetry formalism and MC techniques. This review identified that a commonly used prescription dose of 85 Gy at 5 mm depth in homogeneous medium delivers about 75 Gy and 69 Gy at the same 5 mm depth for specific (125)I and (103)Pd sources, respectively, when accounting for COMS plaque heterogeneities. Thus, the adoption of heterogeneous dose calculation methods in clinical practice would result in dose differences >10% and warrant a careful evaluation of the corresponding changes in prescription doses. Doses to normal ocular structures vary with choice of radionuclide, plaque location, and prescription depth, such that further dosimetric evaluations of the adoption of MC-based dosimetry methods are needed. The AAPM and American Brachytherapy Society (ABS) recommend that clinical medical physicists should make concurrent estimates of heterogeneity-corrected delivered dose using the information in this report's tables to prepare for brachytherapy TPS that can account for material heterogeneities and for a transition to heterogeneity-corrected prescriptive goals. It is recommended that brachytherapy TPS vendors include material heterogeneity corrections in their systems and take steps to integrate planned plaque localization and image guidance. In the interim, before the availability of commercial MC-based brachytherapy TPS, it is recommended that clinical medical physicists use the line-source approximation in homogeneous water medium and the 2D AAPM TG-43U1 dosimetry formalism and brachytherapy source dosimetry parameter datasets for treatment planning calculations. Furthermore, this report includes quality management program recommendations for eye-plaque brachytherapy.
Collapse
|
7
|
Murphree AL, Samuel MA, Harbour JW, Mansfield NC. Retinoblastoma. Retina 2006. [DOI: 10.1016/b978-0-323-02598-0.50028-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
8
|
Astrahan MA, Szechter A, Finger PT. Design and dosimetric considerations of a modified COMS plaque: The reusable “seed-guide” insert. Med Phys 2005; 32:2706-16. [PMID: 16193802 DOI: 10.1118/1.1993828] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
The Collaborative Ocular Melanoma Study (COMS) developed a standardized set of eye plaques that consist of a 0.5 mm thick bowl-like gold alloy backing with a cylindrical collimating lip. A Silastic seed carrier into which 125I seeds are loaded was designed to fit within the backing. The carrier provides a standardized seed pattern and functions to offset the seeds by 1.0 mm from the concave (front) surface of the carrier. These Silastic carriers have been found to be difficult to load, preclude flash sterilization, and are a source of dosimetric uncertainty because the effective atomic number of Silastic is significantly higher than that of water. The main dosimetric effect of the Silastic carrier is a dose-reduction (compared to homogeneous water) of approximately 10%-15% for 125I radiation. The dose reduction is expected to be even greater for 103Pd radiation. In an attempt to improve upon, yet retain as much of the familiar COMS design as possible, we have developed a thin "seed-guide" insert made of gold alloy. This new insert has cutouts which match the seed pattern of the Silastic carrier, but allows the seeds to be glued directly to the inner surface of the gold backing using either dental acrylic or a cyanoacrylate adhesive. When glued directly to the gold backing the seeds are offset a few tenths of a millimeter further away from the scleral surface compared to using the Silastic carrier. From a dosimetric perspective, the space formerly occupied by the Silastic carrier is now assumed to be water equivalent. Water equivalency is a desirable attribute for this space because it eliminates the dosimetric uncertainties related to the atomic composition of Silastic and thereby facilitates the use of either 125I and/or 103Pd seeds. The caveat is that a new source of dosimetric uncertainty would be introduced were an air bubble to become trapped in this space during or after the surgical insertion. The presence of air in this space is modeled and the dosimetric impact discussed. Another unintended consequence of water equivalency is that some fluorescent x rays emitted from the gold backing can now reach the eye. These very low energy x rays were virtually eliminated by absorption in Silastic. When loaded with 125I seeds the modified plaque appears to produce dose distributions that are almost the same as those of the original COMS plaque and the maximum dosimetric uncertainty introduced by an air bubble is about 2%. Dose distributions calculated for a modified plaque loaded with 103Pd seeds show that dose to healthy ocular structures distal to the tumor apex can be reduced compared to 125I. Clearly, it is faster and easier to glue seeds into the reusable gold seed-guide insert than it is to load the COMS-Silastic carrier.
Collapse
Affiliation(s)
- Melvin A Astrahan
- Department of Radiation Oncology, University of Southern California School of Medicine, Los Angeles, California 90033, USA.
| | | | | |
Collapse
|
9
|
Astrahan MA. Improved treatment planning for COMS eye plaques. Int J Radiat Oncol Biol Phys 2005; 61:1227-42. [PMID: 15752905 DOI: 10.1016/j.ijrobp.2004.09.062] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2004] [Revised: 09/28/2004] [Accepted: 09/30/2004] [Indexed: 11/30/2022]
Abstract
PURPOSE A recent reanalysis of the Collaborative Ocular Melanoma Study (COMS) medium tumor trial concluded that incorporating factors to account for anisotropy, line source approximation, the gold plaque, and attenuation in the Silastic seed carrier into the dose calculations resulted in a significant and consistent reduction of calculated doses to structures of interest within the eye. The authors concluded that future eye plaque dosimetry should be "performed using the most up-to-date parameters available." The reason these factors are important is attributable to the low energy (125)I radiation (approximately 28 keV) that is primarily absorbed by the photoelectric process. Photoelectric absorption is quite dependent on the atomic composition of the absorbing material. Being 40% silicon by weight, the effective atomic number of Silastic is significantly greater than that of water. Although the AAPM TG43 brachytherapy formalism inherently addresses the issues of source anisotropy and geometry, its parameter that accounts for scatter and attenuation, the radial dose function g(r), assumes that the source is immersed in infinite homogeneous water. In this work, factors are proposed for (125)I that correct for attenuation in the Silastic carrier and scatter deficits resulting from the gold plaque and nearby air. The implications of using (103)Pd seeds in COMS plaques are also discussed. METHODS AND MATERIALS An existing TG43-based ophthalmic plaque planning system was modified to incorporate additional scatter and attenuation correction factors that better account for the path length of primary radiation in the Silastic seed carrier and the distance between the dose calculation point and the eye-air interface. RESULTS Compared with homogeneous water, the dose-modifying effects of the Silastic and gold are greatest near the plaque surface and immediately adjacent to the plaque, while being least near the center of the eye. The calculated dose distribution surrounding a single (125)I seed centered in a COMS 20 mm plaque was found to be consistent with previously published examples that used thermoluminescent dosimetry measurements and Monte Carlo methods. For fully loaded 12 and 20 mm plaques, calculated dose to critical ocular structures ranged from 16%-50% less than would have been reported using the standard COMS dose calculation protocol. CONCLUSIONS Treatment planning for COMS eye plaques that accurately accounts for the presence of the gold, Silastic and extraocular air is both possible and practical.
Collapse
Affiliation(s)
- Melvin A Astrahan
- Department of Radiation Oncology, University of Southern California Norris Cancer Hospital, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA.
| |
Collapse
|
10
|
Granero D, Pérez-Calatayud J, Ballester F, Casal E, de Frutos JM. Dosimetric study of the 15mm ROPES eye plaque. Med Phys 2004; 31:3330-6. [PMID: 15651616 DOI: 10.1118/1.1812605] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
The main aim of this paper is to make a study of dose-rate distributions obtained around the 15 mm, radiation oncology physics and engineering services, Australia (ROPES) eye plaque loaded with 125I model 6711 radioactive seeds. In this study, we have carried out a comparison of the dose-rate distributions obtained by the algorithm used by the Plaque Simulator (PS) (BEBIG GmbH, Berlin, Germany) treatment planning system with those obtained by means of the Monte Carlo method for the ROPES eye plaque. A simple method to obtain the dose-rate distributions in a treatment planning system via the superposition of the dose-rate distributions of a seed placed in the eye plaque has been developed. The method uses eye plaque located in a simplified geometry of the head anatomy and distributions obtained by means of the Monte Carlo code GEANT4. The favorable results obtained in the development of this method suggest that it could be implemented on a treatment planning system to improve dose-rate calculations. We have also found that the dose-rate falls sharply along the eye and that outside the eye the dose-rate is very low. Furthermore, the lack of backscatter photons from the air located outside the eye-head phantom produces a dose reduction negligible for distances from the eye-plaque r<1 cm but reaches up to 20% near the air-eye interface. Results showed that the treatment planning system lacks accuracy around the border of the eye (in the sclera and the surrounding area) due to the simplicity of the algorithm used. The BEBIG treatment planning system uses a global attenuation factor that takes into account the effect of the eye plaque seed carrier and the lack of backscatter photons caused by the metallic cover, which in the case of a ROPES eye plaque has a default value of T= 1 (no correction). In the present study, a global attenuation factor T=0.96 and an air-interface correction factor which improve on treatment planning system calculations were obtained.
Collapse
Affiliation(s)
- D Granero
- Department of Atomic, Molecular and Nuclear Physics and IFIC, University of Valencia-CSIC, Dr Moliner 50, E46100 Burjassot, Spain
| | | | | | | | | |
Collapse
|
11
|
Krintz AL, Hanson WF, Ibbott GS, Followill DS. A reanalysis of the Collaborative Ocular Melanoma Study Medium Tumor Trial eye plaque dosimetry. Int J Radiat Oncol Biol Phys 2003; 56:889-98. [PMID: 12788199 DOI: 10.1016/s0360-3016(03)00211-6] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE To recalculate the radiation doses delivered to structures of interest within the eye, i.e., the lens, tumor apex, 5-mm point, optic disk, and macula for patients treated with eye plaque radiotherapy on the Collaborative Ocular Melanoma Study (COMS) Medium Tumor Trial, using updated dosimetric data. METHODS AND MATERIALS Using the Plaque Simulator planning system, doses were recalculated for a sampling of COMS patients for each plaque size. Dosimetry parameters incorporated into the recalculation were line source approximation, a 90% Silastic transmission factor, and a 0% gold transmission factor. Generic solutions were generated from the dose recalculations for each plaque size and structures of interest combination. Doses for the remainder of the patient population were recalculated using the generic solutions and compared with the originally reported COMS doses. RESULTS Doses to all structures of interest were reduced 7%-21%, depending on the plaque size and structure combination. The reduction in dose for the macula, optic disc, lens, tumor apex, and 5-mm point was on average 10%, 18%, 8%, 11%, and 12%, respectively. The closer the macula and optic disk were to the plaque rim, the greater the dose reduction. Incorporation of the Silastic transmission factor accounted for a large part of the dose reduction. CONCLUSIONS Incorporating anisotropy, line source approximation, and Silastic and gold shield attenuation into dose recalculations resulted in a significant and consistent reduction of doses to structures of interest within the eyes.
Collapse
Affiliation(s)
- Amanda L Krintz
- Department of Radiation Physics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
| | | | | | | |
Collapse
|
12
|
Nag S, Quivey JM, Earle JD, Followill D, Fontanesi J, Finger PT. The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys 2003; 56:544-55. [PMID: 12738332 DOI: 10.1016/s0360-3016(03)00006-3] [Citation(s) in RCA: 167] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE This article presents the American Brachytherapy Society (ABS) guidelines for the use of brachytherapy for patients with choroidal melanomas. METHODS Members of the ABS with expertise in choroidal melanoma formulated brachytherapy guidelines based upon their clinical experience and a review of the literature. The Board of Directors of the ABS approved the final report. RESULTS Episcleral plaque brachytherapy is a complex procedure and should only be undertaken in specialized medical centers with expertise in this sophisticated treatment program. Recommendations were made for patient selection, techniques, dose rates, and dosages. Most patients with very small uveal melanomas (<2.5 mm height and <10 mm in largest basal dimension) should be observed for tumor growth before treatment. Patients with a clinical diagnosis of medium-sized choroidal melanoma (between 2.5 and 10 mm in height and <16 mm basal diameter) are candidates for episcleral plaques if the patient is otherwise healthy and without metastatic disease. A histopathologic verification is not required. Small melanomas may be candidates if there is documented growth; some patients with large melanomas (>10 mm height or >16 mm basal diameter) may also be candidates. Patients with large tumors or with tumors at peripapillary and macular locations have a poorer visual outcome and lower local control that must be taken into account in the patient decision-making process. Patients with gross extrascleral extension, ring melanoma, and tumor involvement of more than half of the ciliary body are not suitable for plaque therapy. For plaque fabrication, the ophthalmologist must provide the tumor size (including basal diameters and tumor height) and a detailed fundus diagram. The ABS recommends a minimum tumor (125)I dose of 85 Gy at a dose rate of 0.60-1.05 Gy/h using AAPM TG-43 formalism for the calculation of dose. NRC or state licensing guidelines regarding procedures for handling of radioisotopes must be followed. CONCLUSIONS Brachytherapy represents an effective means of treating patients with choroidal melanomas. Guidelines are established for the use of brachytherapy in the treatment of choroidal melanomas. Practitioners and cooperative groups are encouraged to use these guidelines to formulate their treatment and dose reporting policies. These guidelines will be modified as further clinical results become available.
Collapse
Affiliation(s)
- Subir Nag
- Department of Radiation Oncology, Ohio State University, Columbus, OH 43210, USA.
| | | | | | | | | | | |
Collapse
|
13
|
Knutsen S, Hafslund R, Monge OR, Valen H, Muren LP, Rekstad BL, Krohn J, Dahl O. Dosimetric verification of a dedicated 3D treatment planning system for episcleral plaque therapy. Int J Radiat Oncol Biol Phys 2001; 51:1159-66. [PMID: 11704341 DOI: 10.1016/s0360-3016(01)01768-0] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
PURPOSE Episcleral plaque therapy (EPT) is applied in the management of some malignant ocular tumors. A customized configuration of typically 4 to 20 radioactive seeds is fixed in a gold plaque, and the plaque is sutured to the scleral surface corresponding to the basis of the intraocular tumor, allowing for a localized radiation dose delivery to the tumor. Minimum target doses as high as 100 Gy are directed at malignant tumor sites close to critical normal tissues (e.g., optic disc and macula). Precise dosimetry is therefore fundamental for judging both the risk for normal tissue toxicity and tumor dose prescription. This paper describes the dosimetric verification of a commercially available dedicated treatment planning system (TPS) for EPT when realistic multiple-seed configurations are applied. MATERIALS AND METHODS The TPS Bebig Plaque Simulator is used to plan EPT at our institution. Relative dose distributions in a water phantom, including central axis depth dose and off-axis dose profiles for three different plaques, the University of Southern California (USC) #9 and the Collaborative Ocular Melanoma Study (COMS) 12-mm and 20-mm plaques, were measured with a diode detector. Each plaque was arranged with realistic multiple 125I seed configurations. The measured dose distributions were compared to the corresponding dose profiles calculated with the TPS. All measurements were corrected for the angular sensitivity variation of the diode. RESULTS Single-seed dose distributions measured with our dosimetry setup agreed with previously published data within 3%. For the three multiple-seed plaque configurations, the measured and calculated dose distributions were in good agreement. For the central axis depth doses, the agreement was within 4%, whereas deviations up to 11% were observed in single points far off-axis. CONCLUSIONS The Bebig Plaque Simulator is a reliable TPS for calculating relative dose distributions around realistic multiple 125I seed configurations in EPT.
Collapse
Affiliation(s)
- S Knutsen
- Department of Radiophysics, Haukeland University Hospital, Bergen, Norway
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Capote R, Mainegra E, López E. Anisotropy function for 192Ir low-dose-rate brachytherapy sources: an EGS4 Monte Carlo study. Phys Med Biol 2001; 46:1487-99. [PMID: 11384066 DOI: 10.1088/0031-9155/46/5/311] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The anisotropy function of low-dose-rate 192Ir interstitial brachytherapy sources was studied. Absolute dose rates around 192Ir seeds with stainless steel or platinum cladding and a platinum covered wire have been estimated using the EGS4 Monte Carlo simulation system with a very well tested user code. Our results were compared with available experimental data. Excellent agreement between calculated and measured anisotropy function was found for stainless steel clad 192Ir sources, except along the longitudinal axis of the sources. Dosimetry data for the platinum covered seed and 3 mm long wire with platinum cladding as well as for the stainless steel clad 192Ir source are presented in TG43 format. The influence of phantom dimensions on the anisotropy function was found to be non-negligible over 7 cm, enhancing the anisotropy function by 1-2%. Our results have estimated statistical uncertainties below 1% at 1 sigma level up to 10 cm excluding the longitudinal axis where statistical uncertainties below 3% up to 10 cm are observed.
Collapse
Affiliation(s)
- R Capote
- Departamento de Física, Centro de Estudios Aplicados al Desarrollo Nuclear Miramar, La Habana, Cuba.
| | | | | |
Collapse
|
15
|
Yu C, Luxton G. TLD dose measurement: a simplified accurate technique for the dose range from 0.5 cGy to 1000 cGy. Med Phys 1999; 26:1010-6. [PMID: 10436903 DOI: 10.1118/1.598493] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
A simplified TLD technique characterized by high precision and reproducibility of dose measurement is presented. One hundred eighty LiF TLD rods 1 mm diam x 3 mm length as obtained from the manufacturer were annealed for 1 h at 400 degrees C followed immediately by 2 h at 105 degrees C. After exposure to a dose of 1 Gy of 4 MV x rays, TLDs were annealed for 15 min at 105 degrees C, then read out. TLDs were then sorted into five groups, ranging from 26 to 50 rods each with approximately equal sensitivity after correcting for the drift in the sensitivity of the TLD reader during the readout session. Maintaining group identity, the TLDs were again annealed, irradiated and read out. Fewer than 10% of the TLDs were removed from each group because the corrected readings differed from the respective group mean by more than 3.5%. The standard deviation of the readout was approximately 1.5% within each group. The planchet heater was not flushed with nitrogen gas. Various tests were performed to assess the stability of the group sorting technique and the linearity of TLD dose response. After reannealing, five TLDs were randomly drawn from one of the presorted groups, and subjected to various dose of 4 MV radiation over the range from 0.5 to 1000 cGy. This resulted in an average readout standard deviation of 1.2%. Response per unit dose was almost flat over the range from 0.5 cGy to 100 cGy, and increased by 15% over the range from 100 cGy to 1000 cGy. TLD sensitivity was affected by the duration of the anneal, but was virtually independent of the various time delays between irradiation, prereadout anneal, and readout. The group annealing and sorting (GAS) procedure provides a simple, reliable, precise, convenient, and accurate method for TLD measurements.
Collapse
Affiliation(s)
- C Yu
- Department of Radiation Oncology, University of Southern California, School of Medicine, Los Angeles 90033, USA
| | | |
Collapse
|
16
|
Sloboda RS, Wang R. Combined experimental and Monte Carlo verification of 137Cs brachytherapy plans for vaginal applicators. Phys Med Biol 1998; 43:3495-507. [PMID: 9869027 DOI: 10.1088/0031-9155/43/12/008] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Dose rates in a phantom around a shielded and an unshielded vaginal applicator containing Selectron low-dose-rate 137Cs sources were determined by experiment and Monte Carlo simulation. Measurements were performed with thermoluminescent dosimeters in a white polystyrene phantom using an experimental protocol geared for precision. Calculations for the same set-up were done using a version of the EGS4 Monte Carlo code system modified for brachytherapy applications into which a new combinatorial geometry package developed by Bielajew was recently incorporated. Measured dose rates agree with Monte Carlo estimates to within 5% (1 SD) for the unshielded applicator, while highlighting some experimental uncertainties for the shielded applicator. Monte Carlo calculations were also done to determine a value for the effective transmission of the shield required for clinical treatment planning, and to estimate the dose rate in water at points in axial and sagittal planes transecting the shielded applicator. Comparison with dose rates generated by the planning system indicates that agreement is better than 5% (1 SD) at most positions. The precision thermoluminescent dosimetry protocol and modified Monte Carlo code are effective complementary tools for brachytherapy applicator dosimetry.
Collapse
Affiliation(s)
- R S Sloboda
- Department of Medical Physics, Cross Cancer Institute, Edmonton, Alberta, Canada
| | | |
Collapse
|
17
|
Yu C, Luxton G, Apuzzo ML, MacPherson DM, Petrovich Z. Extracranial Radiation Doses in Patients Undergoing Gamma Knife Radiosurgery. Neurosurgery 1997. [DOI: 10.1227/00006123-199709000-00009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
18
|
Yu C, Luxton G, Apuzzo ML, MacPherson DM, Petrovich Z. Extracranial radiation doses in patients undergoing gamma knife radiosurgery. Neurosurgery 1997; 41:553-9; discussion 559-60. [PMID: 9310971 DOI: 10.1097/00006123-199709000-00009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
OBJECTIVE To determine extracranial doses in patients undergoing gamma knife radiosurgery and identify component sources of the extracranial doses using phantom measurements. METHODS The lateral canthi, thyroid, sternum, and midpelvis region were monitored in 104 unselected patients during their gamma knife treatments using thermoluminescent dosimetry. Measured doses were normalized to integral dose, equivalent time (which is defined in relation to the activity of the cobalt-60 sources), and collimator size to correlate radiation doses with these parameters. A phantom was constructed from a polystyrene sphere as a model of the head adjacent to thoracic and pelvic body sections from a commercial humanoid phantom. RESULTS On average, 18 minutes of equivalent time and five isocenters were required to achieve the prescribed dose coverage. The median prescribed dose was 18 Gy. For the lateral canthi, thyroid, sternum, and pelvis, the median doses were 24, 20, 21, and 4 cGy, respectively. Normalization to equivalent time and collimator size was superior to other techniques. Phantom measurements supported the results from patient measurements and further refined estimates of component doses to extracranial sites. CONCLUSION Doses to extracranial sites ranged from 1.5% of the prescribed dose for the lateral canthi to 0.2% for the pelvis. Doses to the sternum and pelvis were proportional to the duration of irradiation. Scatter radiation contributed more than 50% of the dose to the canthi and thyroid. Leakage radiation typically contributed 80 to 90% of the dose to the sternum and pelvis. Radiation during patient couch transit contributed little to the doses at the measured extracranial sites.
Collapse
Affiliation(s)
- C Yu
- Department of Radiation Oncology, University of Southern California School of Medicine, Los Angeles, USA
| | | | | | | | | |
Collapse
|
19
|
Abstract
PURPOSE Episcleral plaque therapy (EPT) with sealed 125I sources is widely used in the treatment of choroidal melanoma. In EPT, as elsewhere in radiotherapy, concern for normal tissue tolerance has frequently been a dose-limiting factor. The concept of conformal therapy, which seeks to improve dose homogeneity within the tumor and greatly reduce the dose to uninvolved structures may provide a solution to this problem. Radioactive sources are typically distributed uniformly over the surface of an episcleral plaque and are sometimes offset slightly from the scleral surface to reduce the dose to the sclera relative to the apex and prescribed therapeutic margin at the tumor base. Nevertheless, it is not uncommon for scleral dose to exceed the dose to the apex of intermediate to tall tumors by a factor of 4 or more. The availability of low-energy sealed sources such as 125I prompted the development of gold-backed plaques to shield noninvolved periocular tissues. The concept of shielding can be extended to include collimation of individual sources. The potential advantages of individual source collimation include reduced scleral dose, more homogeneous tumor dose, and superior shielding of adjacent normal structures such as the fovea as compared to previous plaque designs. METHODS AND MATERIALS A three-dimensional treatment-planning system has been extended to design a plaque that incorporates individually collimated 125I sources. Thermoluminescent dosimetry (TLD) and radiochromic film were used to compare calculated dose-rate distributions with measured dose rates in an acrylic phantom. RESULTS Calculations predict that source collimation in the form of a "slotted" gold plaque will achieve the purposes of the study. The collimating effect of the slots is demonstrated qualitatively using radiochromic film, and the accuracy of the calculation is demonstrated quantitatively with TLD. CONCLUSION The episcleral plaque described in this report is simpler to assemble than previous plaque designs. It produces a more homogeneous dose distribution in the tumor, reduces scleral dose by up to 50% as compared to conventional designs, and significantly reduces radiation dose to uninvolved structures adjacent to the plaque.
Collapse
Affiliation(s)
- M A Astrahan
- Department of Radiation Oncology, University of Southern California School of Medicine, Los Angeles 90033, USA
| | | | | | | |
Collapse
|
20
|
Stevens MA, Turner JR, Hugtenburg RP, Butler PH. High-resolution dosimetry using radiochromic film and a document scanner. Phys Med Biol 1996; 41:2357-65. [PMID: 8938031 DOI: 10.1088/0031-9155/41/11/008] [Citation(s) in RCA: 53] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
A method of reading exposed radiochromic film is described which has significant advantages over conventional densitometry. The method employs a document scanner and associated software for imaging the film. The resulting images are easily analysed using standard software to yield high-resolution dose maps. A calibration was performed which relates scanner signal to dose, allowing for the determination of dose at any point on an exposed film. Results obtained using a broad-band densitometer are compared to those where the scanner has been used. The technique was used to measure the dose distribution around a COMS-type ophthalmic applicator.
Collapse
Affiliation(s)
- M A Stevens
- Department of Physics and Astronomy, University of Canterbury, Christchurch, New Zealand
| | | | | | | |
Collapse
|
21
|
Valcárcel F, Valverde S, Cárdenes H, Cajigal C, de la Torre A, Magallón R, Regueiro C, Encinas JL, Aragón G. Episcleral iridium-192 wire therapy for choroidal melanomas. Int J Radiat Oncol Biol Phys 1994; 30:1091-7. [PMID: 7961016 DOI: 10.1016/0360-3016(94)90314-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
PURPOSE To evaluate the effectivity of high-dose episcleral iridium-192 wires in the treatment of choroidal melanoma. METHODS AND MATERIALS In 1983, the Departments of Radiation Oncology and Ophthalmology at the Clínica Puerta de Hierro, Madrid, Spain, initiated a clinical study using removable episcleral iridium-192 wires in the treatment of choroidal melanoma. Sixty-six evaluable patients were treated from January 1983 through July 1992. Two patients had a small sized tumor (3%), 28 had a medium sized tumor (42%), and 36 patients had a large tumor (54%). The mean follow-up was 40 months (6-118 months). The dose to the apex of the tumor ranged from 66 to 97 Gy (mean 76.6 Gy), and the doses at 2 mm depth ranged from 77 to 433 Gy (mean 200 Gy). RESULTS Tumor regression or stabilization was observed in 53 of the 66 patients (90%). Visual acuity improved following treatment in 5 out of 54 patients (9%), remaining unchanged in 30 out of 54 (56%), and decreased in 19 out of 54 (35%) patients. The remaining seven patients had undergone enucleation. Late complications have been documented in 20 out of 66 patients (30%), including 6 patients in whom enucleation was required because of radiation-related complications. The probability of survival and survival free of local progression was 93% at 5 years and 79% at 10 years. The probability of retaining the treated eye is 82% after the fifth year posttreatment. CONCLUSIONS Treatment of choroidal melanomas with episcleral iridium-192 wires is as effective as treatment with other radioactive applications. We feel that our results using iridium-192 wires are comparable to the other methods. However, we think that our technique is simple to implement, relatively inexpensive, and well tolerated.
Collapse
Affiliation(s)
- F Valcárcel
- Radiation Oncology Department, Universidad Autonoma, Madrid, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Design and methods of a clinical trial for a rare condition: the Collaborative Ocular Melanoma Study. COMS Report No. 3. CONTROLLED CLINICAL TRIALS 1993; 14:362-91. [PMID: 8222668 DOI: 10.1016/0197-2456(93)90052-f] [Citation(s) in RCA: 129] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Investigators who conduct clinical trials of treatments for uncommon conditions face special challenges regarding trial design and execution in addition to the challenges faced by all clinical trial investigators. The Collaborative Ocular Melanoma Study (COMS) currently consists of two multicenter, randomized controlled clinical trials designed to investigate the efficacy of radiotherapy compared to surgery in prolonging the survival of patients with choroidal melanoma, a rare intraocular cancer. Patients with unilateral choroidal melanoma classified as "medium" in size are randomized with equal probability to either enucleation (removal of the eye) or radiation delivered to the tumor by means of a radioactive "plaque" attached by sutures to the scleral surface of the eye over the base of the tumor. Patients with large tumors are randomized with equal probability to either enucleation or a 5 day course of external beam radiation therapy followed by enucleation. Time to death is the primary outcome; patients will be followed for at least 10 years or until death. Quality assurance mechanisms for evaluation, treatment, and follow-up have been implemented. This paper describes the design and methods of the trials, highlights the challenges associated with implementing and conducting the study, and summarizes the current status of the study.
Collapse
|
23
|
Quivey JM, Char DH, Phillips TL, Weaver KA, Castro JR, Kroll SM. High intensity 125-iodine (125I) plaque treatment of uveal melanoma. Int J Radiat Oncol Biol Phys 1993; 26:613-8. [PMID: 8330990 DOI: 10.1016/0360-3016(93)90277-3] [Citation(s) in RCA: 72] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
PURPOSE Episcleral 125I plaque therapy of uveal melanoma is an important treatment modality to control tumor, salvage the globe, and potentially preserve vision. We retrospectively analyzed our experience in 239 patients to assess treatment outcome with this technique. METHODS AND MATERIALS Between 1983 and 1990, 239 uveal melanoma patients were treated with 125I plaques at the University of California, San Francisco. High intensity 125I seeds in the range of 3-20 mCi were used to give a minimum tumor dose of 70 Gy in 4 days. Initial mean tumor size was 10.9 mm x 9.2 mm x 5.5 mm with a range in tumor diameter from 4 to 18 mm and tumor height from 1.9 to 11.1 mm. Best corrected pre-treatment visual acuity was 20/200 or better in 92% of patients. RESULTS Local tumor control was maintained in 91.7% of patients with a mean follow-up of 35.9 months; 19 patients had local tumor progression; mean time to progression was 27.3 mo (1.8 to 60.1 mo). Actuarial local control is 82% at 5 years. Multivariate analysis demonstrates significant correlation of local failure with larger maximum tumor diameter (p = 0.0008), closer proximity to the fovea (p = 0.0001), lower radiation dose (p = 0.0437), and smaller ultrasound height (p = 0.0034). The actuarial incidence of distant metastases is 12% at 5 years with multivariate analysis showing significant correlation only with maximum tumor diameter (p = 0.0064). Visual outcome is 20/200 or better in 58% of patients. CONCLUSION While the tumor control rates appear favorable, ocular morbidity is significant. A current randomized trial comparing 125I plaque with Helium ion therapy is in progress with specific comparison of tumor control, survival, and visual outcome.
Collapse
Affiliation(s)
- J M Quivey
- Department of Radiation Oncology, University of California, San Francisco 94143-0226
| | | | | | | | | | | |
Collapse
|
24
|
|
25
|
Alberti W, Divoux S, Pothmann B, Tabor P, Hermann KP, Harder D. Autoradiography for iodine-125 seeds. Int J Radiat Oncol Biol Phys 1993; 25:881-4. [PMID: 8478240 DOI: 10.1016/0360-3016(93)90319-q] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
To study the interior design of model 6702 and 6711 iodine-125 seeds contact autoradiographs were performed using mammography film. Improved resolution was obtained using a pin-hole camera with a hole of 0.1 mm x 0.1 mm. With these techniques, qualitative determination of the relative activity distribution within each seed was possible. The number of the activated resin spheres and the positions of the centers of these spheres can be exactly determined. A model calculation shows, that variations in the arrangement of the activated spheres within a seed have a moderate influence on the dose distribution at source distances below 10 mm. Knowing the exact source configuration may be useful when comparing dose calculations with measured data for model 6702 125I seeds which are currently employed in ophthalmic plaque and implant therapy of other tumors.
Collapse
Affiliation(s)
- W Alberti
- Klinik für Strahlentherapie und Nuklearmedizin, Alfried Krupp Krankenhaus, Essen, Germany
| | | | | | | | | | | |
Collapse
|
26
|
|
27
|
Abstract
Standardized radioactive plaques have been used in the irradiation of intraocular tumors. These plaques have defined slots to accommodate 125I seeds and hence produce predictable isodose distributions. The seed strength has to be adjusted to deliver 100 Gy to the prescription point, which varies with the tumor size. The purpose of this work is to develop lookup tables that relate the seed strength to different prescription distances. Dose rates were determined for a set of standardized eye plaques. Using these dose rates and the source strength decaying expression, the seed strengths were determined as a function of distance along a line through the plaque. Two seed-strength tables were created based on four-day and five-day treatment times delivering a 100 Gy to the prescription distance.
Collapse
Affiliation(s)
- C B Saw
- Department of Radiation Oncology, University of Pittsburgh School of Medicine, PA 15213
| | | | | | | | | |
Collapse
|
28
|
|
29
|
Petrovich Z, Luxton G, Langholz B, Astrahan MA, Liggett PE. Episcleral plaque radiotherapy in the treatment of uveal melanomas. Int J Radiat Oncol Biol Phys 1992; 24:247-51. [PMID: 1526863 DOI: 10.1016/0360-3016(92)90679-c] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
During an 8-year period, 85 patients with uveal melanomas were treated with episcleral plaque radiotherapy (EPRT). The T-stage was: T1-3 (4%), T2-29 (34%) and T3-53 (62%). The mean tumor elevation was 6.1 mm. Radiation dose was prescribed at the tumor apex and at D5mm. The mean D5mm dose was 150.1 Gy (range 70.5-430 Gy) and the mean dose at the apex was 102.6 Gy (range 29.8-200 Gy). Useful vision (greater than 5/200) was maintained in 73% of patients. The 5-year actuarial survival was 88%. Metastatic disease developed in 9 (11%) patients, 6 of whom died of their disease. Basal tumor dimensions were important factors predicting metastatic disease, p = 0.002. A decrease in tumor evaluation was seen in 82%. There was a much lower incidence of decrease in tumor radial and circumferential dimensions, 47.5 and 46%, respectively, p less than 0.001. Treatment complications were common (56%), particularly in patients with large tumors (72%), p = 0.04. The incidence of complications was higher in patients treated prior to 1988 as compared to those who were treated more recently (67 vs 35%, p = 0.010). There were 13 (15%) patients who had enucleation. This included 12 treated before 1986 and 1 patient treated subsequently (46 vs 2%, p less than 0.001). In a univariate analysis, tumor height and radiation dose at D5mm were important factors predicting enucleation, p = 0.004. In a multivariate analysis, however, the most important factor predicting enucleation was treatment administration prior to 1986, p less than 0.001). A sharp decrease in the incidence of severe complications, including enucleation, as seen after 1985, is likely due to a major effort in treatment optimization.
Collapse
Affiliation(s)
- Z Petrovich
- Dept. of Radiation Oncology, University of Southern California School of Medicine, Los Angeles 90033
| | | | | | | | | |
Collapse
|
30
|
Liggett PE, Ma C, Astrahan M, Pince KJ, Green R, McDonnell J, Petrovich Z. Combined localized current field hyperthermia and irradiation for intraocular tumors. Ophthalmology 1991; 98:1830-5; discussion 1836. [PMID: 1775318 DOI: 10.1016/s0161-6420(91)32042-6] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Ten patients with large melanomas and one patient with recurrent retinoblastoma were treated with combined localized current field (LCF) hyperthermia and iodine 125 irradiation delivered by episcleral plaque. Tumors were heated to 43 degrees to 45 degrees C for 28 to 45 minutes. Localized current field hyperthermia when combined with irradiation appeared to induce rapid tumor necrosis. One eye enucleated 17 hours after treatment showed only focal necrosis of the melanoma, while another eye demonstrated extensive necrosis 60 hours after treatment. In all remaining eyes, tumor regression occurred within the first month of treatment. Complications included cataract formation in six eyes, hemorrhagic retinal detachment in five eyes, and phthisis in two eyes. Complications from combined therapy of large intraocular tumors in this series appeared to result from the rapid necrosis of the tumor and secondary intraocular inflammation. Intraocular temperature dosimetry measurements demonstrated a temperature gradient of not more than -0.23 degrees C/mm-1 per axial millimeter from the episcleral plaque surface to the apex of the tumor. The authors believe that LCF hyperthermia could be a suitable means of application of hyperthermia in patients with intraocular tumors if further modifications were performed to reduce ocular complications.
Collapse
Affiliation(s)
- P E Liggett
- Department of Ophthalmology, University of Southern California School of Medicine, Los Angeles
| | | | | | | | | | | | | |
Collapse
|
31
|
Alberti W, Pothmann B, Tabor P, Muskalla K, Hermann KP, Harder D. Dosimetry and physical treatment planning for iodine eye plaque therapy. Int J Radiat Oncol Biol Phys 1991; 20:1087-92. [PMID: 2022510 DOI: 10.1016/0360-3016(91)90209-m] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The dosimetry of eye plaques loaded with iodine-125 seeds (type 6702) was performed by means of computer calculations and measurements with thermoluminescent dosimeters (TLD). Measurements of the depth dose distribution (2-25.5 mm) along the transverse axis of a single seed were performed in water equivalent phantom material. The transverse axis attenuation and geometry factor F(r) was obtained by applying a least squares fit to the measured data. Based on the resulting radial dose function, a computer program was developed which calculates dose distributions within the eye for arbitrary loading and placement of the eye plaque. The computational results were verified by TLD measurements in an eye phantom.
Collapse
Affiliation(s)
- W Alberti
- Klinik für Strahlentherapie und Nuklearmedizin, Alfried Krupp Krankenhaus, Essen, FRG
| | | | | | | | | | | |
Collapse
|
32
|
Karolis C, Frost RB, Billson FA. A thin I-125 seed eye plaque to treat intraocular tumors using an acrylic insert to precisely position the sources. Int J Radiat Oncol Biol Phys 1990; 18:1209-13. [PMID: 2347728 DOI: 10.1016/0360-3016(90)90459-w] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
A thin re-usable stainless steel ophthalmic applicator is described. The radioactive Iodine-125 sources are inserted in an acrylic button which fits neatly into a stainless steel shell 1 mm thick. The applicator can be assembled with the radioactive sources precisely positioned without the use of adhesives or mechanical devices such as clamps or screws in a matter of a few minutes, (under sterile conditions if necessary). The applicator can be dismantled in seconds after which it is ready for cleaning and re-sterilization. The overall thickness of the plaque is 2.6 mm, but this has the potential to be reduced to 2.1 mm. Suture holes are provided on a flange subtending 120 degrees around the circumference of the shell and are exactly matched on a stainless steel template.
Collapse
Affiliation(s)
- C Karolis
- Department of Medical Physics, Prince of Wales Hospital, Sydney, N.S.W., Australia
| | | | | |
Collapse
|
33
|
Luxton G, Astrahan MA, Findley DO, Petrovich Z. Measurement of dose rate from exposure-calibrated 125I seeds. Int J Radiat Oncol Biol Phys 1990; 18:1199-207. [PMID: 2347727 DOI: 10.1016/0360-3016(90)90458-v] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Dose rate in water 1 cm transverse to an 125I seed calibrated for air kerma strength is not well established; 125I dosimetry calculations are, however, based on this constant. The specific dose constant was obtained from a series of dose rate measurements using thermoluminescent dosimetry (TLD) in a rigid geometry, full scatter acrylic phantom for individual model 6711 seeds. With a statistical precision of approximately +/- .5%, the dose rate to an infinitesimal mass of water located in acrylic at a perpendicular distance of 1 cm from the seed was found to be 0.977 cGy/h per microGy-m2/h of air kerma strength. Dose rate in a water phantom was calculated using a model that takes into account differences in both attenuation and scatter between water and acrylic. The specific dose constant in water was determined to be 0.932 (1.184 cGy-cm2/mCi-h, for the conventional exposure rate constant of 1.45 R cm2/mCi-h). This value is 7.5% less than dose rate in water from an unattenuated point source, and 9.7% less than the value commonly used for dosimetry calculations. The results suggest that most clinical 125I dosimetry estimates to date should be reconsidered for a possible reduction by about 10%. Relative scatter attenuation factors at 3 and 5 mm are also presented.
Collapse
Affiliation(s)
- G Luxton
- Department of Radiation Oncology, University of Southern California School of Medicine, Los Angeles 90033
| | | | | | | |
Collapse
|
34
|
Astrahan MA, Luxton G, Jozsef G, Kampp TD, Liggett PE, Sapozink MD, Petrovich Z. An interactive treatment planning system for ophthalmic plaque radiotherapy. Int J Radiat Oncol Biol Phys 1990; 18:679-87. [PMID: 2318702 DOI: 10.1016/0360-3016(90)90077-w] [Citation(s) in RCA: 76] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Brachytherapy using removable episcleral plaques containing sealed radioisotope sources is being studied as an alternative to enucleation in the treatment of choroidal melanoma and other tumors of the eye. Encouraging early results have been reported, but late complications which lead to loss of vision continue to be a problem. A randomized national study, the Collaborative Ocular Melanoma Study (COMS) is currently in progress to evaluate the procedure. The COMS specified isotope is 125I. Precise dosimetric calculations near the plaque may correlate strongly with complications and could also be used to optimize isotope loading patterns in the plaques. A microcomputer based treatment planning system has been developed for ophthalmic plaque brachytherapy. The program incorporates an interactive, 3-dimensional, solid-surface, color-graphic interface. The program currently supports 125I and 192Ir seeds which are treated as anisotropic line sources. Collimation effects related to plaque structure are accounted for, permitting detailed study of shielding effectiveness near the lip of a plaque. A dose distribution matrix may be calculated in any subregion of a transverse, sagittal, or coronal planar cross section of the eye, in any plane transecting the plaque and crossing the eye diametrically, or on a spherical surface within or surrounding the eye. Spherical surfaces may be displayed as 3-dimensional perspective projections or as funduscopic diagrams. Isodose contours are interpolated from the dose matrix. A pointer is also available to explicitly calculate and display dose at any location on the dosimetry surface. An interactive editing capability allows new plaque designs to be rapidly added to the system.
Collapse
Affiliation(s)
- M A Astrahan
- Department of Radiation Oncology, University of Southern California School of Medicine, Los Angeles 90033
| | | | | | | | | | | | | |
Collapse
|
35
|
Houdek PV, Schwade JG, Medina AJ, Poole CA, Olsen KR, Nicholson DH, Byrne S, Quencer R, Hinks RS, Pisciotta V. MR technique for localization and verification procedures in episcleral brachytherapy. Int J Radiat Oncol Biol Phys 1989; 17:1111-4. [PMID: 2808046 DOI: 10.1016/0360-3016(89)90165-x] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Spatial definition of an intraocular tumor and subsequent determination of the actual position of an implanted eye plaque are essential for adequate ocular brachytherapy treatment planning. However, a method for verification of the plaque placement which would provide required 3-dimensional information is not available at present. In addition, tumor localization procedures, including ultrasonography and CT techniques, cannot always offer the precision needed for 3-dimensional definition of an intraocular target. This communication describes a magnetic resonance imaging technique specifically developed for both localization and verification procedures. A 1.5 Tesla magnetic resonance scanner, spin-echo pulse sequence (echo time 30 msec, repetition time 700 msec), and commercially available surface coil were used to obtain a series of transverse, coronal, and sagittal images of a slice thickness of 3 mm. Usually, eight scans in each of the three planes were needed for adequate coverage of the orbit. The required patient set-up and data acquisition time did not exceed 40 minutes. With a data matrix size of 256 X 256 pixels and 13 cm field of view, localization and verification were accomplished with a precision of 0.5 mm. Our results suggest that the magnetic resonance imaging technique permits precise integration of diagnostic and therapeutic procedures, and in addition provides adequate data for accurate treatment planning. We conclude that magnetic resonance imaging is the preferred diagnostic technique for episcleral brachytherapy.
Collapse
Affiliation(s)
- P V Houdek
- Department of Radiation Oncology, University of Miami School of Medicine, FL
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Karlsson UL, Augsburger JJ, Shields JA, Markoe AM, Brady LW, Woodleigh R. Recurrence of posterior uveal melanoma after 60Co episcleral plaque therapy. Ophthalmology 1989; 96:382-8. [PMID: 2710530 DOI: 10.1016/s0161-6420(89)32882-x] [Citation(s) in RCA: 79] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
The authors analyzed the clinical and follow-up data on 277 selected patients with primary choroidal or ciliochoroidal melanoma who were treated with 60Co plaque radiotherapy between 1976 and 1982. Local recurrence of the irradiated melanoma developed in 39 (14%) patients during the follow-up interval. The 5-year tumor recurrence rate (Kaplan-Meier) was estimated to be 12%. Multivariate prognostic factor analysis (Cox proportional hazards modeling) identified the largest linear tumor dimension and proximity of the posterior margin of the tumor to the optic nerve head as predictors of recurrence. The 5-year survival rate of patients whose tumors recurred (58%) was significantly (log-rank test P = 0.0023) worse than that of patients whose tumor remained clinically controlled (82%).
Collapse
Affiliation(s)
- U L Karlsson
- Department of Radiation Oncology and Nuclear Medicine, Hahnemann University School of Medicine, Philadelphia, PA 19102
| | | | | | | | | | | |
Collapse
|